Clinical Trials
3 trialsNCT07207070 2025-12-30
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 3 Recruiting
NCT06613373 2024-09-25
An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer
Jiangsu Famous Medical Technology Co., Ltd.
Phase 4 Not yet recruiting
NCT05515289 2023-03-10
Study of SHR6390 in Renal Insufficiency and Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown